Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
11.6M
-
Number of holders
-
8
-
Total 13F shares, excl. options
-
400K
-
Shares change
-
+121K
-
Total reported value, excl. options
-
$712K
-
Value change
-
+$222K
-
Number of buys
-
7
-
Number of sells
-
-4
-
Price
-
$1.78
Significant Holders of Apimeds Pharmaceuticals US, Inc. - Common Stock (APUS) as of Q3 2025
12 filings reported holding APUS - Apimeds Pharmaceuticals US, Inc. - Common Stock as of Q3 2025.
Apimeds Pharmaceuticals US, Inc. - Common Stock (APUS) has 8 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 400K shares
of 11.6M outstanding shares and own 3.45% of the company stock.
Largest 10 shareholders include Hemenway Trust Co LLC (250K shares), VANGUARD GROUP INC (59K shares), GEODE CAPITAL MANAGEMENT, LLC (30.8K shares), RENAISSANCE TECHNOLOGIES LLC (27.9K shares), XTX Topco Ltd (18.7K shares), HRT FINANCIAL LP (13.6K shares), BANK OF AMERICA CORP /DE/ (29 shares), JPMORGAN CHASE & CO (8 shares), Tower Research Capital LLC (TRC) (0 shares), and CITADEL ADVISORS LLC (0 shares).
This table shows the top 8 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.